GlassScriptPhysician profile
Timothy Tareque
NPI 1235878547
$2,363.69
in general payments reported to CMS, 2019-2025
25 companies · $610 in 2025
The $610 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $576 · 2023: $532 · 2024: $645 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $477.10 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $317.12 | 2022-2025 | Belbuca |
| Vertex Pharmaceuticals Incorporated | $239.55 | 2025 | |
| Nevro Corp. | $200.62 | 2022-2023 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $155.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.89 | 2023-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $128.94 | 2022 | |
| Pfizer INC. | $120.21 | 2024-2025 | |
| Nalu Medical, INC. | $55.77 | 2023-2024 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $53.99 | 2023 | Mild Device Kit |
| Sanofi-Aventis U.S. LLC | $53.98 | 2022-2023 | |
| Boston Scientific Corporation | $47.47 | 2024 | |
| Mml US, INC. | $43.73 | 2025 | Reactiv8 |
| Forte Bio-Pharma LLC | $41.16 | 2024 | Prolate, Nalocet |
| Spinal Simplicity, LLC | $40.39 | 2025 | Ha Minuteman G3-R |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.23 | 2024-2025 | Eterna, Proclaim |
| Bioventus LLC | $38.07 | 2024 | Durolane |
| Si-Bone, INC. | $34.57 | 2023 | |
| Scilex Pharmaceuticals INC. | $33.02 | 2024-2025 | |
| Ibsa Pharma INC. | $24.36 | 2023 | Tirosint, Licart |
| Merz Pharmaceuticals, LLC | $21.71 | 2022 | |
| Almatica Pharma LLC | $21.63 | 2023 | Gralise |
| Medtronic, INC. | $19.52 | 2024 | Intellis Adaptivestim |
| Redhill Biopharma INC. | $13.83 | 2022 | |
| Hikma Pharmaceuticals USA | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tareque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.